[1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
[2] |
Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China [J]. Ann Surg, 2016, 263(1): 88-95.
|
[3] |
Zheng L, Wu C, Xi P, et al. The survival and the long-term trends of patients with gastric cancer in Shanghai, China [J]. BMC cancer, 2014, 14: 300.
|
[4] |
Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J]. Ann Surg, 1996, 224(4): 509-520; discussion 20-22.
|
[5] |
Bai JG, Lv Y, Dang CX. Adenocarcinoma of the esophagogastric junction in China according to Siewert′s classification [J]. Jpn J Clin Oncol, 2006, 36(6): 364-367.
|
[6] |
Kneuertz PJ, Hofstetter WL, Chiang YJ, et al. Long-term survival in patients with gastroesophageal junction cancer treated with preoperative therapy: do thoracic and abdominal approaches differ? [J]. Ann Surg Oncol, 2016, 23(2): 626-632.
|
[7] |
Martin JT, Mahan A, Zwischenberger JB, et al. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients [J]. J Am Coll Surg, 2015, 220(4): 510-520.
|
[8] |
Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial [J]. Lancet Oncol, 2006, 7(8): 644-651.
|
[9] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4) [J]. Gastric Cancer, 2017, 20(1): 1-19.
|
[10] |
Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma [J]. Gastric Cancer, 2017, 20(Suppl 1): 69-83.
|
[11] |
Collette L, Bosset J F, Den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group [J]. J Clin Oncol, 2007, 25(28): 4379-4386.
|
[12] |
Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 [J]. J Clin Oncol, 2006, 24(28): 4620-4625.
|
[13] |
Illum H. Irinotecan and radiosensitization in rectal cancer [J]. Anticancer Drugs, 2011, 22(4): 324-329.
|
[14] |
Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer [J]. Br J surg, 2013, 100(7): 933-939.
|
[15] |
Probst CP, Becerra AZ, Aquina CT, et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation [J]. J Am Coll Surg, 2015, 221(2): 430-440.
|
[16] |
李俊,崔健,张海增. 直肠癌新辅助治疗后临床完全缓解患者不同处理措施预后效果的Meta分析 [J]. 中国肿瘤外科杂志, 2014, 6(2): 69-76.
|
[17] |
肖巍魏,陈功. 全程新辅助治疗:局部进展期直肠癌的术前治疗新策略 [J]. 中国普外基础与临床杂志, 2017, 24(11): 1311-1315.
|
[18] |
Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group [J]. Eur J Cancer, 2007, 43(14): 2037-2045.
|
[19] |
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases [J]. Ann Surg, 1999, 230(3): 309-318; discussion 318-321.
|
[20] |
Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients [J]. Ann Surg, 2008, 247(1): 125-135.
|
[21] |
van Vledder MG, De Jong MC, Pawlik TM, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? [J]. J gastrointest surg, 2010, 14(11): 1691-1700.
|
[22] |
Bischof DA, Clary BM, Maithel SK, et al. Surgical management of disappearing colorectal liver metastases [J]. Br J Surg, 2013, 100(11): 1414-1420.
|
[23] |
Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stageⅣgastric cancer: the proposal of new biological categories of classification [J]. Gastric Cancer, 2016, 19(2): 329-338.
|
[24] |
Portilla AG, Shigeki K, Dario B, et al. The intraoperative staging systems in the management of peritoneal surface malignancy [J]. J Surg Oncol, 2008, 98(4): 228-231.
|
[25] |
Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer [J]. World J gastrointest oncol, 2010, 2(2): 85-97.
|
[26] |
Japan Intraperitoneal Chemotherapy Study Group (JIPG). The intraperitoneal paclitaxel plus S-1/oxaliplatin for gastric cancer with perioneal metastasis: SOX+IP PTX trial (Phase II study) [J]. ASCO, 2016, Abstract No.4040.
|
[27] |
Yamaguchi K, Yoshida K, Tanahashi T, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy [J]. Gastric Cancer, 2018, 21(2): 315-323.
|
[28] |
Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial [J]. Lancet Oncol, 2016, 17(3): 309-318.
|
[29] |
Kemeny N. Management of liver metastases from colorectal cancer [J]. Oncology (Williston Park), 2006, 20(10): 1161-1176, 1179; discussion 1179-1180, 1185-1186.
|
[30] |
Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? [J]. J Surg Oncol, 2012, 106(2): 193-196.
|
[31] |
Yoshida K, Yamaguchi K, Okumura N, et al. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer [J]. Pathobiology, 2011, 78(6): 343-352.
|